Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

10 Sept 2009

Abstract excerpt

BACKGROUND: During the last few years an increasing number of poly(ADP-ribose) polymerase (PARP) inhibitors have been appearing in the context of cancer therapy. This is mainly due to a better knowledge of the best-characterized member of the PARP family of enzymes, PARP-1, further reinforced by the recognition of the clinical benefits arising from its inhibition. OBJECTIVE/METHOD: The aim of this review is to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to PARP inhibition in cancer therapy
Share to Sirtuins and Resveratrol in Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19743897
DOI: 10.1517/13543770903215883

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?PMID 19743897Read ↗

PARP inhibitors in cancer therapy: an updateSemantic proximity Read ↗

Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancersSemantic proximity Read ↗

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other DiseasesSemantic proximity Read ↗

Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivoSemantic proximity Read ↗

Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future OpportunitiesSemantic proximity Read ↗

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.Semantic proximity Read ↗

Recent Progress in Poly(ADP–Ribose) Polymerase‐1 Inhibitors for Application in CancerSemantic proximity Read ↗

PARP inhibitorsSemantic proximity Read ↗

PARP (Poly ADP‐ribose Polymerase) Family in Health and DiseaseSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].Semantic proximity Read ↗

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.